Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From BioArctic AB

Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

Deals Business Strategies

Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s

More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.

Clinical Trials Research & Development

Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis

As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period… 

BAN2401 Results Validate Eisai/Biogen's Faith In Alzheimer's Amyloid Tack

In the wake of multiple recent drug failures in the Alzheimer's sector, Eisai and partner Biogen announce "impressive" top-line results for an amyloid-targeting antibody that provide important support for the amyloid hypothesis and may also bode well for the companies' lead candidate in the same class.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • BioArctic Neuroscience AB
UsernamePublicRestriction

Register